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Antibody drug conjugates (ADCs) are a therapeutic
class offering promise for cancer therapy. The
attachment of cytotoxic drugs to antibodies can
result in an effective therapywith better safety poten-
tial than nontargeted cytotoxics. To understand the
role of conjugation site, we developed an enzymatic
method for site-specific antibody drug conjugation
using microbial transglutaminase. This allowed us
to attach diverse compounds at multiple positions
and investigate how the site influences stability,
toxicity, and efficacy. We show that the conjugation
site has significant impact on ADC stability and phar-
macokinetics in a species-dependent manner. These
differences can be directly attributed to the position
of the linkage rather than the chemical instability,
as was observed with a maleimide linkage. With
this method, it is possible to produce homogeneous
ADCs and tune their properties to maximize the ther-
apeutic window.
INTRODUCTION
There has been a recent rise in the number of antibody drug
conjugates (ADCs) being developed as promising therapeutic
agents with increased antitumor effectiveness and reduced
toxicity compared to traditional chemotherapy (Junutula et al.,
2010; Lambert 2012; Senter 2009; Senter and Sievers 2012)
These conjugates have been manufactured largely using chem-
ical conjugation methods, where the cytotoxic drug is covalently
attached to lysines or cysteines on the antibody, typically
through N-hydroxysuccinimide ester or maleimide functionality,
respectively. These methods generally result in conjugates that
are heterogeneous mixtures of ADCs bearing varying numbers
of drugs attached at different positions on the antibody molecule
(Wang et al., 2005), with each subpopulation of the mixtureChemistry & Biology 20, 161having different physical and pharmacokinetic (PK) properties
(Hamblett et al., 2004). Methods of conjugation using engineered
cysteines or incorporation of unnatural amino acids have been
reported to improve the homogeneity of ADCs (Axup et al.,
2012; Junutula et al., 2008; McDonagh et al., 2006). Junutula
et al. (2008) developed cysteine-based site-specific conjuga-
tion called ‘‘THIOMABs’’ (TDCs) that are claimed to display an
improved therapeutic index as compared to conventional conju-
gation methods. This approach has enabled the generation of
nearly homogeneous conjugates containing fewer drugs per
antibody than conventional ADCs without the presence of signif-
icant amounts of unconjugated antibody. Engineered cysteine-
based conjugation, however, requires a reduction-oxidation
step, which can result in residual reactivity of native cysteines.
The reduction-oxidation step together with the presence of
unpaired cysteines in expressed IgGs (Chumsae et al., 2009)
might contribute to product heterogeneity. Moreover, the intro-
duced cysteines have been observed to form triple light chain
species (Gomez et al., 2010a, 2010b), and thiol-maleimide
linkage employed in TDCs can undergo decoupling and toxin
loss (Alley et al., 2008; Shen et al., 2012), although this can be
ameliorated by careful selection of the conjugation site (Shen
et al., 2012). Conjugation to unnatural amino acids that have
been incorporated into the antibody is also being explored for
ADCs; however, the generality of this approach is yet to be es-
tablished (Axup et al., 2012).
RESULTS AND DISCUSSION
Previously, the effect of drug loading on PK has been demon-
strated; however, the intrinsic heterogeneity of conventional
ADCs and limited conjugation sites available has precluded the
study of the effect of conjugation site on PK and potentially effi-
cacy and safety. To study how the site of conjugation influences
the various attributes of an ADC, we sought a method that would
address the above limitations and still allow conjugation through
a range of sites on the antibody. We have developed an orthog-
onal enzymatic conjugation approach using transglutaminase
from Streptoverticillium mobaraense, which is inexpensive and
commercially available in large quantities. Similar to mammalian–167, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 161
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Figure 1. Transglutaminase-Catalyzed Site-Specific Conjugation of Antibody Drug Conjugates
(A) Chemical reaction catalyzed by transglutaminase.
(B) Positions found to conjugate at high efficiency. The two positions (C16-HC and C16-LC) chosen for further characterization are circled.
(C) Examples of cytotoxic drugs and fluorophores that were conjugated to antibodies.
(D) Hydrophobic interaction chromatography analysis of C16-HC-AcLys-vcMMAD (red) and C16-LC-AcLys-vcMMAD (blue). Antibodies (C16-HC and C16-LC)
prior to conjugation are shown as black lines.
(E) Intact mass deconvolution of C16-HC-AcLys-vcMMAD and C16-LC-AcLys-vcMMAD. The mass difference between the peaks corresponding to DAR 1 and 2
is approximately 1,330Da, which is themass of the cytotoxic drug.Most of the antibody is conjugatedwith two drugs; a smaller fraction is conjugated to one drug.
See also Figure S1.
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Conjugation Site Changes ADC Stability and PKtransglutaminases, mTG catalyzes the formation of a covalent
bond between a glutamine side chain and a primary amine (Fig-
ure 1A) and has been extensively used as a protein crosslinking162 Chemistry & Biology 20, 161–167, February 21, 2013 ª2013 Elseagent (Yokoyama et al., 2004). Although mTG shows some
promiscuity in its recognition sequence (Ohtsuka et al., 2000a),
we and others have shown that it does not recognize naturallyvier Ltd All rights reserved
Table 1. Drug Loading at Selected Sites in Multiple Antibodies
Ab Chain Position
Antibody
Anti-EGFR Anti-HER2 Anti-M1S1
Alexa488
Cadaverine vcMMAD
Alexa488
Cadaverine vcMMAD
HC N-term 1.2
HC C-term 1.8 1.9 1.7 1.9
HC 135 1.9 1.9 1.8
HC 160 1.9 1.8 1.4
HC 190 1.7 1.7 1.7
HC 222 1.8 1.7 1.4
HC 251 1.9 2 1.9
HC 294 1.9 1.8 1.8
HC 385 2
LC 168 1.9
LC 200 2 1.9 1.7
LC C-term 1.9 1.8
Glutamine tag LLQG was introduced at multiple positions in an antibody
and screened using anti-EGFR antibody and Alexa488. Positions that
showed good conjugation efficiency (maximum loading is 2.0) were
also tested on anti-HER2 and anti-M1S1 antibodies with either Alexa488
cadaverine or vcMMAD.
Chemistry & Biology
Conjugation Site Changes ADC Stability and PKoccurring glutamines in the constant regions of glycosylated
antibodies (Jeger et al., 2010; Strop et al., 2012), providing us
with the opportunity to design a specific ‘‘glutamine tag’’ that
can be engineered at desired locations. The orthogonal nature
of the mTG technology also allows combination with current
conjugation technologies and site-specific attachment of mul-
tiple drugs.
The mTG conjugation allows us to explore conjugation posi-
tions and simplified linker chemistries. We carried out a sys-
tematic scan of antibody constant domains by engineering a
glutamine tag (LLQG) into surface accessible regions of an
anti-EGFR (epidermal growth factor receptor) IgG1 antibody to
find positions that allow efficient conjugation and useful proper-
ties. Out of the approximately 90 sites that were tested, we found
12 sites with good biophysical properties and a high degree
of conjugation (Figure 1B; Table 1; Table S1 available online).
Next, we examined the ability of mTG to accommodate diverse
linkers and payloads. We found that by introducing appropriate
amine containing linkers (Ohtsuka et al., 2000b), mTG is able
to conjugate structurally diverse probes and drugs. Examples
of well-conjugating molecules include amine-containing deriva-
tives of various fluorophores and the potent tubulin inhibitor,
MMAD (Miyazaki et al., 1995) (monomethyl dolastatin 10), with
both cleavable and noncleavable linkers as shown in Figure 1C.
Comparable conjugation efficiency and selectivity were ob-
served for IgG1, IgG2, and IgG4 antibody subtypes (data not
shown). To further examine the transferability of our mTG
method to other antibodies of interest, we also engineered
selected glutamine tags into an anti-M1S1 antibody C16 and
an anti-Her2 antibody and observed similar conjugation efficien-
cies (Table 1).
For subsequent experiments, we focused on comparing ADCs
generated using two distinct conjugation sites: one on the heavyChemistry & Biology 20, 161chain (C16-HC) and one on the light chain (C16-LC). The C16-HC
construct contains an LLQGA tag in place of the C-terminal
lysine on the heavy chain, whereas the C16-LC construct
contains GGLLQGA following the C-terminal cysteine residue
on the light chain. The C16 antibody does not recognize the
mouse or rat M1S1 protein and therefore the toxicities and phar-
macokinetics reported in the following experiments are not
target dependent. Antibodies engineered with glutamine tags
were conjugated with the same cleavable AcLys-vc-MMAD
payload and linker (Figures 1B and 1C) to compare the proper-
ties of the two sites of conjugation. We utilized hydrophobic
interaction chromatography (HIC) and intact mass spectrometry
(MS) to determine the relative distribution and loading of conju-
gates. The conjugation to the C16-HC site yielded a product
with the average drug-antibody ratio (DAR) of 1.9 per expected
maximum of 2.0 (Figure 1D), which migrated as 99%monomeric
species on size-exclusion chromatography, and the C16-LC site
resulted in a conjugate with the average DAR of 1.8 (maximum
2.0) and was 98.5% monomeric (data not shown). Intact and
reduced liquid chromatography-mass spectrometry analysis
confirmed the loading ratios for each conjugate (Figure 1E) and
attachment to the appropriate antibody chain (Figures S1A
and S1B). Liquid chromatography-tandem mass spectrometry
peptide mapping showed cytotoxic drug attachment to the
engineered glutamine tag on the antibody (Figures S1C–S1E),
demonstrating a high degree of efficiency and site specificity
of the transglutaminase conjugation.
The ability to generate homogeneous populations of ADCs
with mTG technology allows us to look at how different sites
of conjugation influence efficacy, stability, pharmacokinetics,
and toxicity. Potency of the C16-HC and C16-LC conjugated
with AcLys-vc-MMAD (C16-HC-AcLys-vc-MMAD and C16-LC-
AcLys-vc-MMAD) was evaluated both in vitro and in vivo. The
two conjugates showed similar cell killing in vitro with IC50 values
of 0.053 and 0.054 nM, respectively, in BxPC3 pancreatic cancer
cell line (M1S1 +++) and 0.058 and 0.075 nM in the A431 epider-
moid carcinoma cell line (M1S1 +++) (Figures 2A and 2B). The
efficacy of the two conjugates was comparable to the conven-
tional cysteine conjugate C16-mc-vcMMAD with higher loading
(DAR 3.6), which had an IC50 of 0.04 nM and 0.033 nM in the
BxPC3 and A431 cell lines, respectively. All conjugates were
almost 3,000 times less potent in a non-M1S1-expressing
SW620 cell line (Figure 2C).
Both C16-HC-AcLys-vcMMAD and C16-LC-AcLys-vcMMAD
were also highly potent in vivo (Figure 2D). Mice implanted with
BxPC3 cells were given a single intravenous dose of the ADC
and monitored for up to 10 weeks postdose. Single doses of
either C16-HC-AcLys-vcMMAD (DAR 1.9) or C16-LC-AcLys-
vcMMAD (DAR 1.8) at 3 mg/kg were able to induce similar tumor
shrinkage percentages on week 1 and week 2 to the conven-
tional conjugate (DAR 3.6, 3 mg/kg) tested in another study
(Figures 2E and 2F). In both studies the tumor regression effects
were sustainable and lasted up to 10 weeks.
Pharmacokinetic properties of C16-HC-AcLys-vcMMAD and
C16-LC-AcLys-vcMMAD were examined in SCID mice. Animals
were given a single 9 mg/kg intravenous dose, and plasma
samples were analyzed for the presence of the C16 anti-
body (total antibody ELISA). C16-HC-AcLys-vcMMAD and
C16-LC-AcLys-vcMMAD displayed similar PK profiles to the–167, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 163
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Figure 2. In Vitro and In Vivo Efficacy of the Conventional C16-mc-vcMMAD and Site-Specific C16-HC-AcLys-vcMMAD and C16-LC-AcLys-
vcMMAD Conjugates
(A–C) Cytotoxicity of C16-HC-vc-AcLys-vcMMAD and C16-LC-vc-AcLys-vcMMAD were evaluated on target-expressing (A) BxPC3, (B) A431, or (C) non-target-
expressing SW620 cells as described in the Supplemental Experimental Procedures.
(D and E) In vivo efficacy of negative control (mc-vcMMAD with DAR of 4.4) and C16 conventional cysteine conjugates (C16-mc-vcMMAD with DAR 3.6) or C16-
HC-AcLys-vcMMAD and C16-LC-AcLys-vcMMAD TG conjugates (DAR of 1.9 and 1.8, respectively) were tested on BxPC3 pancreatic xenograft model.
(F) Comparison of tumor size for all conjugates and negative controls tested in the two studies relative to the starting tumor size. (+) 100% indicates doubling in
tumor size, whereas (-) 50% indicates decrease in tumor size by a half. In (A)–(C), error bars represent SD; (E) and (F) error bars represent SEM.
See also Figure S2 and Table S1.
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Conjugation Site Changes ADC Stability and PKunconjugated C16 antibody for the first week after dosing. In
the second week, C16-LC-AcLys-vcMMAD remained similar to
the unconjugated C16 antibody, whereas the C16-HC-AcLys-
vcMMAD showed somewhat accelerated clearance (Figure 3A).164 Chemistry & Biology 20, 161–167, February 21, 2013 ª2013 ElseTo address whether the PK profile is consistent among species,
we also examined the total antibody PK in Sprague Dawley rats.
Although the C16-LC-AcLys-vcMMAD PK remained similar to
the unconjugated C16 PK, C16-HC-AcLys-vcMMAD showedvier Ltd All rights reserved
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Figure 3. Pharmacokinetics and ADC
Stability of C16-HC-AcLys-vcMMAD and
C16-LC-AcLys-vcMMAD Conjugates
(A–H) Serum levels of total antibody for uncon-
jugated C16 antibody compared to C16-HC-
AcLys-vcMMAD and C16-LC-AcLys-vcMMAD
conjugates in mice (A) and rats (B). Comparison of
total antibody and ADC levels determined by
ELISA inmouse (C) or rat (D) serum. In vivo stability
and drug loading measurements as described in
the Supplemental Experimental Procedures for
C16-HC-AcLysMMAD (E) and C16-HC-AcLysM-
MAD (F) in mice andC16-HC-AcLysMMAD (G) and
C16-HC-AcLysMMAD (H) in rats. Error bars
represent SD.
See also Figure S3 and Tables S2 and S3.
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Conjugation Site Changes ADC Stability and PKa significantly different profile, with an 83% loss of the antibody
from the serum in the first 24 hr postdose (Figure 3B). Analysis of
FcRn binding of C16-HC-AcLys-vcMMAD and C16-LC-AcLys-
vcMMAD by surface plasmon resonance showed no significant
differences between them, or their unconjugated parents, in their
affinities to purified recombinant mouse, rat, cyno, and human
FcRn proteins at pH 5.8 and pH 7.4 (Figure S3A).
Because the total antibody ELISA used in these experiments
does not measure the drug attached to the antibody, the differ-
ential PK profile of C16-HC-AcLys-vcMMAD and C16-LC-
AcLys-vcMMAD cannot be attributed to drug loss from the
ADC. Junutula et al. (2008) reported that cysteine site-specific
anti-MUC16 conjugate showed little difference in PK between
mouse and rat, whereas conventional MUC16 mc-vcMMAE
conjugate cleared more rapidly in rat but not in a mouse. Our PK
data for C16-LC conjugate shows a similar trend to the anti-
MUC16 site-specific conjugate, where no difference between
mouse and rat was observed. However, our second site-specific
conjugate C16-HC shows a similar trend in PK to conventional
anti-MUC16 conjugate, where rat and mouse PK differs. How-
ever, in our case the site-specific nature of the conjugate
unequivocally identifies the observed difference to be likely a
result of differential in vivo distribution of the ADC that is influ-
enced by the position of the MMAD drug on the antibody and
its exposure to the surrounding tissues.
The stability of the C16-HC-AcLys-vcMMAD and C16-LC-
AcLys-vcMMAD was assessed by comparison of the total anti-
body ELISA and anti-MMAD ELISA using anti-human IgG and
anti-MMAD monoclonal antibodies. The area under the curve
of the mAb and ADC for both mouse and rat studies are shown
in Table S3. Using these assays, both C16-HC-AcLys-vcMMAD
and C16-LC-AcLys-vcMMAD showed comparable drug loss in
mice (Figure 3C), whereas in rats C16-LC-AcLys-vcMMAD ap-
peared to be more stable (Figure 3D). Although informative, the
anti-MMAD ELISA does not quantitatively distinguish between
DARof 1.0 andDARof 2.0 and thus can bemisleading.We there-
fore purified the C16 ADCs from in vivo experiments and
analyzed their drug loading by HIC and mass spectrometry
(Figures 3E–3H). Samples from the in vivo mouse stability assay
revealed the absence of the DAR 1.0 species in both the C16-
HC-AcLys-vcMMAD and C16-LC-AcLys-vcMMAD conjugates
(Figures 3E and 3G). This observation suggests that the cleavage
of the DAR 1.0 proceeds relatively quickly in mice compared
to the DAR 2.0, and single drug loaded antibodies do not
accumulate in the vascular compartment. In contrast, the DAR
1.0 appears more stable in rats and is readily detected for
the C16-HC-AcLys-vcMMAD (Figure 3F). The C16-LC-AcLys-
vcMMAD appeared very stable in rats, and therefore no signifi-
cant change in the DAR distribution was observed (Figure 3G).
Mass spectrometry analysis of C16-HC-AcLys-vcMMAD and
C16-LC-AcLys-vcMMAD purified from in vivo plasma samples
revealed that the stability of transglutaminase conjugates is
not governed by a spontaneous loss of payload-linker, as has
been observed for some maleimide conjugates (Alley et al.,
2008; Shen et al., 2012). In samples purified from both mice
and rats, the antibodies without the toxin moiety still contained
the AcLys-Val-Cit linker conjugated to the glutamine tag but
lost the PABC-MMAD portion of the payload (Figures S3B–
S3F). Comparable results were also obtained when conjugates166 Chemistry & Biology 20, 161–167, February 21, 2013 ª2013 Elsewere incubated with mouse and rat sera in vitro, suggesting
that background levels of proteases capable of cleavage of the
AcLys-Val-Cit linker exist in mice and rat serum and that the
transglutaminase linkage is stable both in vitro and in vivo
(data not shown).
Taken together, in rat we observe differences in cleavage and
pharmacokinetics of ADCs conjugated at two different sites
(C16-HC and C16-LC), whereas in mouse, these differences
are not apparent. C16-LC-AcLys-vcMMAD appeared to be
more stable in rat, with very little drug loss observed after
1 week, and showed nearly identical PK profile to the wild-type
C16 antibody. The C16-HC-AcLys-vcMMAD, on the other
hand, showed dramatically different PK from the unconjugated
C16 antibody in rat and a faster rate of drug loss. The loss of
drug proceeds via a different mechanism than that observed
for maleimide ADCs, with proteolysis occurring at the Cit-
PABC linkage. This observation suggests that low levels of
proteases capable of the AcLys-Val-Cit cleavage exist in mouse
and rat sera but that the levels and/or activities of these prote-
ases must be somewhat different because of the differential pro-
cessing of DAR 1.0 species.
We evaluated the off-target safety of the C16-HC-AcLys-
vcMMAD and C16-LC-AcLys-vcMMAD at 10 and 25 mg/kg in
Sprague Dawley rats (Figure S2). Serum levels of liver enzymes
aspartate aminotransferase (AST) and alanine transaminase
(ALT) were not significantly elevated at either 10 or 25 mg/kg
dose for both conjugates. A significant decrease in neutrophils
was observed at 25 mg/kg for both C16-HC-AcLys-vcMMAD
and C16-LC-AcLys-vcMMAD but not at 10 mg/kg (Figure S2).
Both site-specific conjugates were tolerated in rats at 10 and
25 mg/kg, whereas animals did not tolerate 10 mg/kg dose
of the non-cross-reactive conventional mc-vcMMAD conjugate
at loading of 3.6 (data not shown). Comparable efficacy of the
conventional mc-vcMMAD conjugate to the site-specific C16-
HC-AcLys-vcMMAD and C16-LC-AcLys-vcMMAD conjugates
in the BxPC3 mouse model was noted (Figures 2D and 2E), but
differential toxicity from conventional conjugate in rat suggests
that either the selected position of the drug or the lower loading
can improve therapeutic indices of ADCs. Comparable findings
were also reported for the MUC16 site-specific THIOMABs
(Junutula et al., 2008).
SIGNIFICANCE
Here, we show that the drug position can have a significant
effect on linker stability and antibody pharmacokinetics.
These observations do not pertain as much to the instability
of the chemical linkage as shownby others (Shen et al., 2012)
but rather to an inherent property of the site of attachment.
We also demonstrate that the site of conjugation can influ-
ence ADC properties differently in mice and rats, high-
lighting potential pitfalls of examining efficacy in mouse
xenograft models and toxicity in rats or nonhuman primates.
These studies were made possible by developing mTG-
based conjugation technology and the appropriate linker
chemistry, which offers a precise control over the site of
conjugation and the drug:antibody stoichiometry, allowing
us to generate homogeneous conjugates in a reproducible
manner. Large amounts of mTG available from commercialvier Ltd All rights reserved
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Conjugation Site Changes ADC Stability and PKsources, and expression levels of the tagged mAbs that
are comparable to those of unmodified mAbs, make this
approach easily scalable. In comparison to other site-
specific technologies (Axup et al., 2012; Junutula et al.,
2008), the transglutaminase-based conjugation can provide
stable ADCs, prepared using highly specific enzymatic
chemistry that does not suffer from issues pertaining to
manufacturing (i.e., high reactant stoichiometry and low
cell-line titers) of unnatural amino-acid-based approaches
(Axup et al., 2012) or instability and difficulties (i.e., multiple
light chains) associated with maleimide and thiol chemis-
tries (Gomez et al., 2010a, 2010b; Shen et al., 2012). Our
data highlight the utility of site-specific conjugation in not
only generating homogeneous and reproducible ADCs but
also the ability to dissect the role of position, linker, and
payload in an effort to optimize the therapeutic index of
these molecules.
EXPERIMENTAL PROCEDURES
Experimental methods are described in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.01.010.
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